Clinical trials: Solid and Hematological Malignancies
- Condition Solid and Hematological Malignancies
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Cancer, Solid Tumor
Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA
Nucleix EpiCheck® tests analyzes the methylation pattern in a panel of DNA methylation biomarkers and determines whether this pattern is consistent with cancer under test or with non-cancer tissue.
- Conditions
- Cancer, Solid Tumor, Hematologic Neoplasms
- Trial name
- NCT04264767
- Testing
- Blood collection
- Where
- 3 sites in United States, Israel
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Nucleix Ltd.
Solid and Hematological Malignancies
Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants
This is a two-part, open-label, randomized, crossover study in healthy subjects (vasectomized males and women of non-childbearing potential), performed at 2 study centers
- Trial name
- NCT04944771
- Testing
- Capivasertib, Rabeprazole
- Where
- Germany
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hematologic Malignancy, Solid Tumor
Multiple Ascending Dose Study of CG200745 'Ivaltinostat' Oral Capsule
A Phase I, Double blind, Randomized, Placebo-controlled, Multiple Ascending Dose Study to evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Orally Administered 'CG-745' Capsule in Healthy Male Volunteers
- Conditions
- Hematologic Malignancy, Solid Tumor, Fibrosis
- Trial name
- NCT05716919
- Testing
- Ivaltinostat
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Machaon Biotherapeutics, Inc.
Hepatic Impairment
Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment
The main purpose of this study is to evaluate the effect of varying degrees of impaired hepatic function (by Child Pugh classification) on the plasma PK of siremadlin after a single oral dose.
- Trial name
- NCT05599932
- Testing
- Siremadlin
- Where
- 3 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Cancer, Solid Tumor Cancer
Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in Cancer
This study entails enrolling participants that have been diagnosed with cancer to Olivia, a commercially available AI-enabled personal health platform developed by Tempus.
- Conditions
- Cancer, Solid Tumor Cancer, Pediatric Acute Myeloid Leukemia, Hematologic Malignancies
- Trial name
- ONCO-OLIVIA (NCT07756034)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Tempus AI